Vir Biotechnology

Update in progress

VIR (NasdaqGS)

Company RatingNeutral
SectorHealthcare
IndustryBiotechnology

Vir Biotechnology is a clinical-stage biopharmaceutical company focused on discovering and developing therapies to treat and prevent serious infectious diseases, with a global reach. Its pipeline includes investigational therapies targeting hepatitis delta virus and various solid tumors. Preclinical programs cover influenza A and B antibodies, coronavirus monoclonal antibodies, and PRO-XTEN dual-masked T cell engagers. It collaborates with and licenses to multiple partners and is based in San Francisco, founded in 2016.

Company score

Sentiment: 0.38; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.15; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.11; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.07; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.23; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive